ASLAN PHARMACEU/ADR (NASDAQ:ASLN) had its price target dropped by stock analysts at HC Wainwright from $9.00 to $2.00 in a research note issued on Thursday, The Fly reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 400.00% from the company’s previous close. The analysts noted that the move was a valuation call.
A number of other research firms have also weighed in on ASLN. Zacks Investment Research raised shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 target price on the stock in a research note on Monday, November 4th. Piper Jaffray Companies lowered shares of ASLAN PHARMACEU/ADR from an “overweight” rating to a “neutral” rating in a research note on Monday, November 11th. BTIG Research lowered shares of ASLAN PHARMACEU/ADR from a “buy” rating to a “neutral” rating in a research note on Monday, November 11th. Finally, ValuEngine raised shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. ASLAN PHARMACEU/ADR currently has a consensus rating of “Buy” and an average price target of $3.67.
ASLN traded down $0.05 during trading on Thursday, reaching $0.40. The company’s stock had a trading volume of 44,900 shares, compared to its average volume of 24,522. The company has a quick ratio of 3.80, a current ratio of 1.88 and a debt-to-equity ratio of 1.12. The firm has a fifty day simple moving average of $1.53 and a two-hundred day simple moving average of $2.59. ASLAN PHARMACEU/ADR has a 1 year low of $0.35 and a 1 year high of $6.48. The company has a market cap of $14.10 million, a price-to-earnings ratio of -0.29 and a beta of 2.40.
About ASLAN PHARMACEU/ADR
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Further Reading: How is the LIBOR rate calculated?
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.